|
|
|
|
|
|
|
|
|
|
|
|
|
01.05.26 - 13:06
|
ING Group Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für ING nach Quartalszahlen von 28,50 auf 29,50 Euro angehoben und die Einstufung auf "Buy" belassen. Die Kennziffern der Großbank seien besser als erwartet ausgefallen, schrieb Johan ......
|
|
|
01.05.26 - 13:06
|
Aon Plc Q1 Income Rises (AFX)
|
|
|
LONDON (dpa-AFX) - Aon plc (AON) announced a profit for its first quarter that Increases, from the same period last yearThe company's bottom line totaled $1.212 billion, or $5.63 per share. This c......
|
|
|
|
|
|
|
01.05.26 - 13:06
|
Nebius Agrees to Acquire Eigen AI, Strengthening Nebius Token Factory as a Frontier Inference Platform (Business Wire)
|
|
|
Combines Eigen AI's industry-leading inference stack with Nebius's global capacity
Jointly optimized endpoints achieved top rankings on Artificial Analysis across multiple models
Eigen AI's founding team, including MIT HAN Lab researchers, will establish Nebius's Bay Area engineering and research presence
AMSTERDAM--(BUSINESS WIRE)--Nebius (NASDAQ: NBIS), the AI cloud company, today announced an agreement to acquire Eigen AI, a leading inference and model optimization company.
The acquisition will strengthen Nebius Token Factory as a frontier managed inference platform for production AI, combining a battle-tested optimization stack with Nebius's global compute capacity and AI cloud platform, and will add elite inference research talent to the company's established in-house AI R&D capabilities.
Following close, Eigen AI's inference and post-training optimization layers will be integrated directly into Nebius Token Factory, which provides enterprise-grade autoscaling endpoints and fine-tuning pipelin...
|
|
|
|
|
01.05.26 - 13:03
|
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling (GlobeNewswire EN)
|
|
|
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumor microenvironment (TME). MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast activation protein (FAP), which is expressed in high amounts in the stroma of various solid tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alle News zu Europa 5890.7335 0.0% (E.St.50 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
